Abstract: The present disclosure generally relates to a capacitor on an integrated circuit (IC) die. In an example, a package includes first and second IC dice. The first IC die includes a first circuit, a capacitor, and a polyimide layer. The first circuit is on a substrate. The capacitor includes a bottom plate over the substrate and a top plate over the bottom plate. The polyimide layer is at least partially over the top plate. A distance from a top surface of the top plate to a bottom surface of the polyimide layer is at least 30 % of a distance from a top surface of the bottom plate to a bottom surface of the top plate. A signal path, including the capacitor, is electrically coupled between the first circuit and a second circuit in the second IC die, which does not include a galvanic isolation capacitor in the signal path.

Abstract: A microelectronic device includes a semiconductor substrate and a high voltage isolation capacitor over the substrate. The capacitor includes a bottom capacitor plate over the substrate. Dielectric layers are formed above the bottom capacitor plate, including a top dielectric layer. A high dielectric layer on the top dielectric layer includes at least a first sublayer having a first dielectric constant that is higher than a dielectric constant of the top dielectric layer. A top capacitor plate is formed on the high dielectric layer over the bottom capacitor plate. An electric field abatement structure surrounds the top capacitor plate. The electric field abatement structure includes a shelf of the high dielectric layer extending outward from a lower corner of the bottom capacitor plate at least 14 microns, and an isolation break in the high dielectric layer past the shelf, in which the first sublayer is removed from the isolation break.

Abstract: A product returns processing system may include mobile devices communicating respective purchase transaction receipts for respective products. The system may also include a returns processing server including a processor and a memory. The memory may store the purchase transaction receipts, for each product, a product return rule, a product availability status, and a disposition, and for each user, a return mode preference. The processor may determine a return expiration for each product based upon a respective product return rule, send a notice to each mobile device based upon a respective return window expiration, and receive a return request. The processor may, when the request is received before a return expiration, determine a product availability and condition, determine a return address based upon the disposition and at least one of the product availability and condition, and generate a label with the return address and based upon the return mode preference.

Abstract: Various embodiments of the invention provide human proteins associated with cell growth, differentiation, and death (CGDD) and polynucleotides which identify and encode CGDD. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CGDD.

Abstract: The invention provides human cytoskeleton-associated proteins (CSAP) and polynucleotides which identify and encode CSAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CSAP.

Abstract: The invention provides human protein phosphatases (PP) and polynucleotides which identify and encode PP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PP.

Abstract: The invention provides human protein phosphatases (PP) and polynucleotides which identify and encode PP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PP.

Abstract: The invention provides GTPase activating proteins, their encoding cDNAs, and antibodies that specifically bind the proteins. The invention also provides for the use of these compositions in the diagnosis, prognosis, treatment and evaluation of progression and treatment of signaling, immune, and cell proliferative disorders, particularly colon cancer.

Abstract: The invention provides mammalian nucleic acid molecules and fragments thereof. It also provides for the use of the mammalian nucleic acid molecules for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with cell signaling, the immune system, and cell proliferation, particularly colon cancer. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecules.

Abstract: The invention provides methods for treating abnormal uterine bleeding via application of compounds that block uterine stromal cell response to angiogenic growth factors by interfering with the growth factors themselves, by blocking receptors in the uterine epithelial or stromal cells to those growth factors, and/or by inhibiting other receptors to those growth factors. The compounds include interferons, particularly type I interferons, pirfenidone, heparin, heparin-like polyaromatic anionic compounds, heparin-sulfate-based compounds, secreted or soluble FGF receptors, and/or RGD-peptide. The angiogenic growth factors to which response is blocked include basic fibroblast growth factor (bFGF), FGF receptors (FGFR), acidic fibroblast growth factor (aFGF), transforming growth factor &bgr; (TGF-&bgr;), platelet-derived growth factor (PDGF), heparin binding epidermal growth factor (HBEGF), vascular endothelial growth factor (VEGF), parathyroid hormone-related protein (PTHrP) and/or prolactin.